Thymosin Alpha-1
NOT FDA APPROVEDImmune-modulating peptide
Also known as: Tα1, Zadaxin, thymalfasin
Not FDA approved in the US. Approved in around 35 other countries (as Zadaxin) for hepatitis and as an immune adjunct.
A real evidence base, with gaps
- Regulatory standing. Sold as a research chemical, not approved
- Human trials. Backed by controlled human studies
- Registered human trials. 64 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: genuine immune-modulating activity, with approvals abroad and human studies as an adjunct in hepatitis, some infections, and certain cancers. NOT established in the US regulatory system, and the broad 'immune boost' framing outruns the specific evidenced uses.
What it is
A naturally occurring thymic peptide that modulates T-cell and innate immune function.
What the research says
Approved in many countries and studied as an adjunct in infections and some cancers, though not FDA approved in the US.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Thymosin Alpha-1 in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling.
Thymosin stimulates secretion of luteinizing hormone-releasing factor.
Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Thymosin Alpha-1 is the intervention being tested.
Immuno-effect of Tα1 for Stage I NSCLC
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
Abscopal Effect for Metastatic Colorectal Cancer
FDA recalls & enforcement
Thymosin Alpha-1 has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Not FDA approved in the US; US gray-market product is unverified.
- Best evidence is for specific medical adjunct uses, not general 'immunity'.
Doses reported in studies & protocols
Dosing in approved markets is set by the label. This is not a recommendation.
Purity reality
US supply is gray-market and unverified.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.